Fact CheckerSign in

NCT06151223Recruiting

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

Source: ClinicalTrials.gov · Last updated 10 Mar 2026

Brief summary (registry, in English)

This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.

Status (registry)
Recruiting
Study type
Observational
Enrollment
5000 (estimated)
First submitted
21 Nov 2023
Start date
13 Jul 2021
Primary completion date
31 Jul 2031
Lead sponsor
Mayo Clinic
NCT number
NCT06151223

What you commit to

  • Study type: Observational
  • Planned participants: 5000
  • From 13 Jul 2021 to the primary completion date, 31 Jul 2031
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Individual who has a personal history of pancreatic ductal adenocarcinoma (PDAC)
  • History of total pancreatectomy

Who the study is looking for

  • Age ≥ 18 year
  • Able to provide written informed consent
  • Meets criteria as a High-Risk Individual as defined by protocol

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Mayo Clinic in Rochester
Coordinator of this site? Confirm its status
RochesterUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.